



Smart Nanocarriers for Drug Delivery in Colon Cancer

Guest Editors:

Dr. Milena A. Vega

Departamento de Ingeniería
Química y Textil, Universidad de
Salamanca, Pl/La Merced s/n,
37008 Salamanca, Spain

Dr. Celia Nieto

Section of Immunobiology,
University of León, Campus de
Vegazana s/n, 24071 León, Spain

Prof. Dr. Gema Marcelo

Department of Analytical
Chemistry, Physical Chemistry
and Chemical Engineering, Pza.
San Diego, s/n, 28801 Alcalá de
Henares, Spain

Deadline for manuscript
submissions:

closed (20 April 2023)

Message from the Guest Editors

Dear Colleagues,

Despite advances in the diagnosis and treatment of colorectal cancer, its incidence is increasing at an alarming rate, and it is currently the third most common cause of cancer-related death worldwide. As with most solid tumors, one of the most challenging issues in colon cancer therapy is associated with the severe side toxicity of chemotherapeutic drugs. Thus, there is an urgent need to reproducibly develop effective targeted nanocarriers capable of preventing drug adsorption and degradation in the upper gastrointestinal tract, and thus capable of transporting chemotherapeutic drugs to the colon.

This Special Issue aims to collect recent trends in the field of colon cancer therapy related to the use of nanocarriers capable of promoting active targeting in the tumor microenvironment. Thus, we welcome articles on the development, characterization and validation of liposomes, nanoparticles, nanohydrogels and nanocomposites conjugated with selective targeting molecules and/or stimuli-responsive, designed to improve the main drawbacks of traditional chemotherapy.

Dr. Milena A. Vega

Dr. Celia Nieto

Dr. Gema Marcelo

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of
Pharmacy, Rutgers, The State
University of New Jersey, William
Levine Hall, Room 225C, 160
Frelinghuysen Road, Piscataway,
NJ 08854-8020, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma